Brief: Ultimovacs Announces Protocol Amendment In UV1 Phase II Study Initium In Malignant Melanoma

Zelluna ASA

31/10/2023 06:14

Oct 31 (Reuters) - Ultimovacs ASA  ULTI.OL :
    * ANNOUNCES PROTOCOL AMENDMENT IN UV1 PHASE II STUDY INITIUM IN MALIGNANT MELANOMA
    * PATIENTS IN INITIUM STUDY ARE TAKING LONGER THAN EXPECTED TO EXPERIENCE CANCER PROGRESSION
    * AMENDED PROTOCOL IN INITIUM ENABLES DATA ANALYSIS TO START MID-JANUARY 2024
    * TOPLINE RESULTS FROM RANDOMIZED PHASE II STUDY EXPECTED TO BE ANNOUNCED ABOUT 2-3 MTHS
LATER

Source text for Eikon:  ID:nGNE8TC8wM 
Further company coverage:  ULTI.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))